Nick Diakopoulos: Artificial intelligence and journalism beyond the hype
Professor Nick Diakopoulos speaks to iMEdD about how generative artificial intelligence is affecting newsrooms and journalism’s comparative advantage in content production. He comments on the competitive pressures media face in distribution and sees the opportunity for trust in journalism as still very much alive.
Between sunscreen and AI
Every month we pull together tools, research, and ideas for journalists wearing… many hats.
Good journalism is essential, but not enough
Good journalism is essential but not enough, when it’s up against corrupt institutions, eroded powers, financial interests, or, hundreds of times worse, ruthless governments wielding massive military power.
Israel’s killing of journalists follows a pattern of silencing Palestinian media that stretches back to 1967
For The Conversation writes Maha Nassar, Associate Professor in the School of Middle Eastern and North African Studies, University of Arizona.
Bridging distances through the power of collaboration
About two months ago, a different cycle of the iMEdD incubator came to a close — the first one designed exclusively for journalists from Greece’s local press.
What to Add to Your Journalistic Suitcase
The iMEdD team has compiled and recommends books, podcasts, series, and documentaries — by journalists or about journalism — that are worth our time during the holidays.
Editorial cartooning: From pen to AI (and back again)
Can a cartoon be "born" from an algorithm? If so, what does this mean for the future of satire and commentary? An AI researcher and four cartoonists speak to iMEdD. The latter explain why, after experimenting, they chose to leave it out of the picture —for now.
En route to a “functional cure” for HIV
After four decades of human coexistence with HIV, what are the latest developments that raise hopes and expectations for a future “functional cure”? With this question in mind, we traveled to New York, visited Rockefeller University, and met with scientists, people living with HIV and participants in clinical trials. We talked about what science knows today, what modern research is looking for, and what the community anticipates.
Abuse of power and the public interest with Paul Caruana Galizia
ALSO VISIT
